LONG-TERM RESULTS OF USING THE KEMANGIOPROTEZ VASCULAR XENOGRAFT IN COMPARISON WITH THE VENAFLO II EPTFE VASCULAR GRAFT IN PATIENTS UNDERGOING CHRONIC HEMODIALYSIS

Highlights For the first time, the long-term outcome of using the KemAngioprotez vascular xenograft as a permanent vascular access in patients undergoing chronic hemodialysis will be described and comparative assessed with synthetic Venaflo II ePTFE vascular graft. Abstract Aim. To study whether the KemAngioprotez vascular xenograft is an effective alternative to Venaflo II ePTFE vascular graft in patients undergoing chronic hemodialysis. Methods . The study included 44 patients with KemAngioprotez vascular xenograft and 26 patients with Venaflo II ePTFE vascular graft. The follow-up period was ≥ 12 months from the moment of the creation of permanent hemodialysis vascular access. The endpoints of the study included the patency of the prosthesis, which was assessed over a period of 3.6 and 12 months, respectively, as well as adverse events: death from any cause, infectious complications, bleeding from the prosthesis, aneurysm and thrombosis of the prosthesis. Results . Based on a comparative analysis and a comparison of long-term results, there were no statistically significant differences in adverse events during the 12-month follow-up period. The indicators of the primary and secondary endpoint after 12 months in the KemAngioprotez group were 1.375 and 1.789 times higher, respectively, compared with the Venaflo II group. Venaflo II ePTFE grafts are 2,593 times more susceptible to infectious complications. Synthetic grafts, in this study, are devoid of such a complication as aneurysmal dilation, in comparison with the KemAngioprotez vascular xenograft. Conclusions . In clinical practice, when providing vascular access for long-term renal replacement therapy, the KemAngioprotez vascular xenograft is an effective alternative to the Venaflo II ePTFE vascular graft. The disadvantages of vascular xenografts are aneurysmal dilatations, the advantages are a low risk of infectious complications.